Replies to post #234637 on Biotech Values

[LongRun8]

"blemish-free"...Clever. I see what you did there.

[Bickema]

RVNC - Dew did they raise the Fintech TAM to $700 million from $500 million? I can't remember what the previous slide said.

Also, if you wouldn't mind, in layman's terms, tell me how Revance will generate revenue from their Hint MD acquisition. I.e. revenue that will be recorded as Hint MD or Fintech. TIA

[stockbettor]

The recent upsurge in RVNC volume -- particularly yesterday -- has probably been triggered by Brent Saunders formation of a SPAC. An IPO was publicly announced on Thursday. RVNC closely fits the profile of the type of target company described in the IPO materials that the SPAC will seek to acquire.

Note that although RVNC's trading volume soared yesterday, relatively large block trades in RVNC began appearing in mid-August. I have reproduced below a short description of the SPAC from Renaissance Capital, as well as a link to the IPO filing.

Vesper Healthcare Acquisition Filed Terms, Nasdaq: VSPRU
Blank check company formed by the former CEO of Allergan targeting the healthcare sector.

Industry: SPAC
We are a newly incorporated blank check company. While we may pursue an acquisition opportunity in any industry or sector, we intend to focus on the pharmaceuticals and healthcare sectors with an emphasis on companies in the medical aesthetics, eye care, longevity and wellness categories. Our founders possess a unique combination of executive, strategic, operational, financial and transactional experience in these sectors, and have demonstrated a strong track record of creating significant shareholder value at leading pharmaceutical, healthcare, biotechnology and aesthetics companies. We believe that the experience and expertise of our founders will make us an attractive partner to potential target businesses, enhance our ability to complete a successful business combination and bring value to the business following our initial business combination. Our management team is led by Brenton L. Saunders and Manisha Narasimhan, Ph.D. Mr. Saunders and Dr. Narasimhan collectively have over four decades of experience identifying, acquiring, operating and creating shareholder value as the leaders of top pharmaceutical, biotechnology and aesthetics companies.
https://www.renaissancecapital.com/Profile/VSPRU/Vesper-Healthcare-Acq/IPO

https://www.sec.gov/Archives/edgar/data/1818093/000121390020026107/fs12020_vesperhealthcare.htm#T17